**Booster Innovation Scheme** 

# **Booster Innovation Fund Quarterly Client Update**

Update as at and for the quarter ending 30 September 2024

#### **Portfolio Performance**

The Booster Innovation Fund (BIF) has had a negative quarter ending 30 September 2024, returning -0.5% for the quarter and 14.5% p.a. since inception (24 August 2021) (after fees and before tax).


There have been valuation movements in several of the companies invested in, with some experiencing uplifts in response to their business and investment activities, and others adjusted downwards to reflect slower than expected progress.

As at the end of September, the Booster Innovation Fund has equity/equity-like assets and cash of \$19.8m.

### **Portfolio Additions and Exits**

This quarter, BIF welcomed **Mars Bioimaging** to our portfolio, starting with an initial investment of \$75k, part of a planned \$400k to be invested in tranches.

**Mars Bioimaging** specialises in advanced spectral molecular imaging. Their technology combines the best of X-ray, CT, MRI, and PET scans to produce 3D, high-resolution, colour images with exceptional clarity. Partnering with the world's top musculoskeletal research centre and the leading US orthopaedic network, HSS, **Mars** is at the forefront of disruptive medical imaging globally. Our co-investment will help **Mars** secure FDA approval in the US and drive future revenue growth.



#### **Key Facts**

Fund Size (net asset value)	\$19.8 million
Inception Date	24/08/2021
Manager	Booster Investment Management Ltd
Supervisor	Public Trust
Fund Type	Portfolio Investment Entity (PIE)

#### Performance as at 30 September 2024

BIF was created in August 2021. Potential returns on early stage businesses are uncertain, difficult to predict and can range widely both positively and negatively. By taking a portfolio approach to investing, the Booster Innovation Fund aims to deliver a significant total rate of return over rolling 15-year periods. Past performance is not an indicator of future performance.

	Before Tax	After Tax (28%)
Last 3 months	-0.5%	-0.6%
Last 6 months	-1.1%	-1.1%
Last 12 months	-1.6%	-1.8%
Last 2 years (p.a.)	4.8%	4.5%
Last 3 years (p.a.)	15.0%	15.5%
Since Inception 24/8/21 (p.a.)	14.5%	15.0%

All figures are after fees. Please see the Product Disclosure Statement for further details. After tax return may be higher than before tax due to tax credits from performance based fees.

#### **Risk Level**

Early stage company investing is generally considered the riskiest type of equity investing. While the fund is not required to calculate a Risk Indicator based on the volatility of the fund (being the extent to which the fund's assets go up and down), we consider the fund's risk rating would equate to 7 on a scale of 1 (low) to 7 (high).



Please see the Product Disclosure Statement for a description of the circumstances that the manager is aware of that exist or are likely to arise that significantly increase the risk to returns for investors in the Booster Innovation Fund.





#### **Portfolio Spotlight**

Gaining international traction is an essential part of an early-stage company's journey to grow value. Several BIF portfolio companies are making strides on the global stage, forming international partnerships and attracting offshore investors, which is adding value to each business and the BIF portfolio.


Allegro has developed a water-based electrolyte solution for long-duration energy storage that is safe and sustainable. They've partnered with Australian energy leader Origin to test their system on a large scale. In August 2024, Allegro completed their AUD \$17.5 million Series A funding round, led by US venture capital firm The Graham Foundation, alongside other offshore investors like Lightbank, Melt Ventures, and Impact Ventures. This international backing gives Allegro access to global markets, crucial capital networks, and valuable entrepreneurial expertise driving future growth. **MACSO** is creating an Al-powered sensory platform. The team have now formed several strategic partnerships including leading global technology provider Avnet to advance Al models on hardware, disruptive Al solution industry leader Chaoyang Technologies in Shanghai, and US-based Piera Systems to develop devices capable of detecting vape smoke. Early momentum in major global markets is a strong indicator of **MACSO**'s growth potential.

Scentian Bio has developed a groundbreaking digital system that replicates insect receptors to identify taste and smell. They've formed key partnerships with leading global food companies and recently won first place in a major food science competition in Chicago, drawing the attention of brands like Coca-Cola and Pepsi. Scentian Bio is working with Britain's Oxford Nanopore to manufacture handheld devices and with San Diego-based Cardea Bio to integrate their technology with graphene transistor nanochips.

#### **BIF Investment Holdings**

BIF holds interests in a portfolio of over 30 investments with a total value of \$19.8m, across a range of business sectors as follows. We intend to grow a more diversified portfolio, indicatively more than 40.

#### Portfolio value by sector



Part of the fund's investments are held by investing in NZ Innovation Booster LP (NZIB). For further information of how we invest through NZIB refer to the Product Disclosure Statement on the booster.co.nz website.

## Description of Individual Holdings

Company⁰	Company Stage	Description
Advemto Limited <sup>1</sup>	Early stage	Sell ultrafast spectroscopy systems, that can reduce research analysis from months to days.
Alimetry Limited <sup>1,2</sup>	Expansion	Sell non-invasive devices for aiding informed diagnostics for gastric disease.
Allegro Energy Pty Limited <sup>1</sup>	Early stage	Developing high performance water-based electrolytes provide a low cost, clean and green energy storage solution.
Amaroq Therapeutics Limited <sup>1</sup>	Seed	Developing a new class of therapeutics that target long non-coding RNA in cancer.
Avasa Limited	Seed	Commercialising a novel implantable medical device that aids in complex microvascular artery and vein reconstruction.
BioLumic Inc	Expansion	Improves crop yield and quality by treating seeds and seedlings with UV-light recipes.
B.spkl Limited	Seed	Commercialising a unique manufacturing method and materials technology to produce a key component of hydrogen electrolysers, aiming to facilitate viable green hydrogen production.
Calocurb Limited	Early stage	Developing a bioactive ingredient, sourced from New Zealand hops, to assist people with chronic and debilitating obesity, a growing health epidemic internationally.
Captivate Technology Limited	Seed	Developing a novel method of carbon capture, with potential to sequester greenhouse gas emissions across a range of industries.
Codify Asset Solutions (CAS) Limited <sup>1,2,3</sup>	Early stage	Sell software that automates compliance, management, and auditing of infrastructure assets.
Chitogel Limited <sup>1</sup>	Expansion	Sell sinus dressings that helps to enhance wound healing and improve patient outcomes post-surgery.
Ferronova Pty Limited <sup>1</sup>	Expansion	Developing surgical tracer systems that are designed to more accurately map cancer spread to lymph nodes.
Hot Lime Labs Limited	Early stage	Developing carbon capture systems to convert wood biomass into a more sustainable source of CO2 for use in horticulture.
Inhibit Coatings Limited <sup>1</sup>	Early stage	Developing coatings to inhibit microbial contamination and outbreaks in facilities with high hygiene requirements.
InsituGen Limited <sup>1</sup>	Expansion	Developing testing solutions for the detection of performance enhancing drug use in animals and humans.
Jaipuna Limited <sup>3</sup> (trading as Amy.app)	Early stage	Providing an online private tutor for maths that makes learning maths easy for everyone.
Komodo Holdings Limited	Early stage	Helping teachers and schools track the wellbeing of students using an interactive wellbeing platform.
Liquium Limited <sup>1</sup>	Seed	Seeking to revolutionise the ammonia production process making it cleaner, cheaper and scalable.
MACSO Technologies Limited	Seed	Developing cloud based monitoring systems utilising human-like sensors and on-edge artificial intelligence to monitor changes in the built environment.
Marama Labs Limited <sup>1</sup>	Early stage	Develops scientific hardware and data analytics solutions to help wineries improve the quality of their wine production.

Mars Bioimaging Limited	Expansion	Provides advanced spectral molecular imaging. Their technology combines the best of X-ray, CT, MRI, and PET scans to produce 3D, high-resolution, colour images for use in healthcare.
Montoux Limited	Expansion	Provides an actuarial Automation and Decision Science platform specifically designed for life and health insurers
My Better Breathing Limited (trading as Good Air Nosebuds)	Seed	Developing a mechanical breathing technology to improve natural function and reduce nasal congestion.
Opo Bio Limited	Seed	Produces living and non-living ingredients for the production of the fast growing cultivated meats sector.
Orbis Diagnostics Limited	Early stage	Developing point of care diagnostics for use in pharmacy and other settings.
Scentian Bio Limited	Early stage	Commercialising a unique sensing system, based on insect sensing receptors, that can define a digital reference for a taste and smell.
Sensor Holdings Limited (trading as StretchSense)	Expansion	Sell motion capture gloves that combine sensors and machine learning for finger tracking in animation and gaming.
TamoRx Limited <sup>3</sup>	Seed	Specialise in the development of novel drugs which arm the immune system to help fight cancer.
Tasmanlon Limited <sup>1</sup>	Seed	Developing aluminium-ion battery technologies suited for grid storage and portable applications.
The Sustainable Care Company (trading as Cleanery)	Expansion	Sell a range of eco-friendly cleaning and personal care products that aim to have a reduced environmental impact compared to existing solutions.
Upstream Medical Technologies Limited <sup>1</sup>	Early stage	Developing novel cardiac biomarkers to diagnose specific heart conditions rapidly and accurately.
Wellumio Limited <sup>1</sup>	Seed	Developing portable, magnetic resonance imaging (MRI) device to improve stroke treatment model.
Woolchemy NZ Limited	Early stage	Utilising wool to create intelligent eco-logical materials for personal care products.
Whole Fish Limited (trading as New Fish)	Seed	Developing marine whey, a protein source produced from water and microalgae.
XFrame Pty Limited <sup>1</sup>	Expansion	Sell recoverable, reusable building frames for sustainable construction.
ZeroJet Limited	Expansion	Selling electric jet propulsion systems, seeking to eliminate the need for combustion engines on small watercraft.

<sup>o</sup> Companies that have advised the Manager that they have been put into liquidation (and the Manager has valued at nil) are not included.

<sup>1</sup> Investments are held indirectly via an interest in NZIB.

<sup>2</sup> Investments are held indirectly via NZIB which has an interest in the specific investees through an agreement with the Matū Karihi fund.

<sup>3</sup> Companies have advised the Manager that it is currently in hibernation. The Manager has adjusted down the valuation accordingly.

For more information visit "The BIF Story" at our website.

The Booster Innovation Fund (fund) is part of the Booster Innovation Scheme which is issued and managed by Booster Investment Management Ltd (Booster). The fund's Product Disclosure Statement is available at **www.booster.co.nz**, by contacting your financial adviser or by calling Booster on **0800 336 338**.

Disclaimer: This document is for information purposes only. The information is derived from sources believed to be accurate as at the date of issue and may change. The content is of a general nature and does not take into account your financial situation or goals and is not financial advice. Booster, its related companies, directors, board members and nominees do not accept any liability for any loss or damage arising directly or indirectly out of the use of, or reliance on, the information provided in this document, nor do they guarantee the fund's performance, returns or repayment of capital.